First-in-class precision targeted approach for cancer therapy
Advancing Cancer Medicine
A new treatment platform compatible with other treatment modalities to improve patient outcomes and survival
Transforming the Lives of patients
We are for the patients, to provide them with new options to battle and cure the disease
Aspyrian Therapeutics, Inc. is a Clinical Stage Biotechnology Company Developing Precision Targeted Approaches to Treat Cancer
Aspyrian Therapeutics, Inc., is a privately funded clinical stage biotechnology company developing a new class of precision targeted oncologic drugs for the treatment of solid tumors based on a Photoimmunotherapy platform.
The Company's first product, RM-1929, is in clinical phase 1/2 testing to treat recurrent Head and Neck Cancer patients. For information about the trial and for enrollment considerations please contact Dr. Biel at Merrill_Biel@aspyriantherapeutics.com or visit the information at Clinicaltrials.gov.
Aspyrian Therapeutics Inc., has secured the exclusive license to develop treatments based on the Photoimmunotherapy platform.
Aspyrian Therapeutics Inc, holds the exclusive license of the Photoimmunotherapy from the National Cancer Institute (NCI, USA). This technology utilizes cancer-targeting antibodies conjugated to a photoactivatable molecule. These conjugates are laser-activated at the tumor site to induce rapid, effective, and specific cancer cell destruction.